Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCB-NK Cells in Recurrent Ovarian Carcinoma
NCT03539406Phase 1Completed
- Sponsor
- Radboud University Medical Center
- Start
- Jun 2019
- Primary completion
- May 2023
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of umbilical cord blood-derived NK cells in ovarian carcinoma, fallopian tube carcinoma (PFTC) and primary peritoneal carcinoma (PPC) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Incidence of treatment emergent adverse events at 6 months. Started Jun 2019; status: completed.
02
Drugs
umbilical cord blood-derived NK cells
03
Conditions
ovarian carcinomafallopian tube carcinoma (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT03539406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03539406.